Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout
Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-endFavorable safety profile observed to date, with limited hematological
A medicine company finished testing different doses of a new drug on 76 patients and will share early results by the end of the year. So far the drug looks safe, which is a good sign to watch for when they release the full results.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.